Summary
The pharmacokinetic parameters (AUC, Cmax, Tmax, and t1/2) of nifedipine following single oral administration of a 10 mg capsule of test product were compared to those of the same amount of a reference product. The two products in capsule form were administered according to a randomized two-way crossover design in 22 healthy male volunteers. Nifedipine plasma concentrations were determined using a rapid, sensitive and precise high performance liquid chromatography (HPLC) method with ultraviolet (UV) detection at 235 nm. The parametric 90% confidence intervals of the mean value of the ratio [Myograd® (test product) /Adalat® (reference product)] for pharmacokinetic parameters were 0.90–1.08, 0.80–1.07, and 0.93–1.12 for AUC0⇌∞, Cmax and t1/2, respectively. In each case, values were within the acceptable bioequivalence range of 0.8–1.25. Distribution free point estimate for the difference in expected medians of Tmax of the two products (Myogard®-Adalat®) was 0.00 h with a 90% confidence interval of 0.00–0.13 which is greater than the accepted bioequivalence of ±0.12. The kinetic parameters were comparable to those reported for nifedipine, and no statistically significant differences were found in any of them when comparing the two products by analysis of variance (ANOVA) on log-transformed data. Thus, the two products could be considered bioequivalent regarding absorption rate (Cmax and Tmax), extent of absorption (Cmax and AUC) and elimination (t1/2)
Similar content being viewed by others
References
Sorkin E.M., Clissold S.P., Brogden R.N. (1985): Nifedipine, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in ischemic, heart disease, hypertension and related cardio-vascular disorders. Drugs, 30, 182–274.
Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. (1996): Goodman and Gilman, The Pharmacological Basis of Therapeutics, 9th Edn. New York: McGraw Hill, 635–636.
Shaheen O., Zmeili S., Al-Qussuois Y., Arafat T., Mouti H. (1991): Pharmacokinetics and pharmacodynamics of two commercial oral nifedipine products. Int. J. Clin. Pharmacol. Ther. Toxicol., 29, 337–341.
Kleinbloesem C.H., van Brummelen P., Faber H., Danhof M., Vermeulen N.P.E., Breimer D.D. (1984): Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem. Pharmacol., 33, 3721–3724.
Foster T.S., Hamann S.R., Richards V.R., Bryant P.J., Graves D.A., McAllister R.G. (1983): Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J. Clin. Pharmacol., 23, 161–170.
Gutierrez L.M., Lesko L.J., Whipps R., Carliner n., Fisher M. (1986): Pharmacokinetics and pharmacodynamics of nifedipine in patients at steady state. J. Clin. Pharmacol., 26, 587–562.
Bolton S. (1990): Pharmaceutical Statistics, Practical and Clinical Application. New York: Marcel Dekker, 122–128.
El-Sayed Y.M., Niazi E.M., Khidr S.H. (1993): High-performance liquid chromatographic method for the determination of nifedipine in plasma and its use in pharmacokinetic, studies. J. Clin. Pharm. Ther., 18, 325–330.
Shumaker R. (1986): PKCALC, a basic interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab. Rev., 17, 331–348.
Sauter R., Steinijans V.W., Diletti E., Böhm A., Schulz H.U. (1992): Presentation of results of bioequivalence studies. Int. J. Clin. Pharmacol. Ther. Toxicol., 30, 233–256.
Schulz H.U., Steinijans V.W. (1991): Striving for standards in bioequivalence assessment: a review. Int. J. Clin. Pharmacol. Ther. Toxicol., 29, 293–298.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rawashdeh, N.M., Battah, A.H., Irshaid, Y.M. et al. Comparative pharmacokinetics of two nifedipine products in capsule form following single oral administration in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics 22, 259–264 (1997). https://doi.org/10.1007/BF03189816
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03189816